Seeing is believing: In vivo evolution of multiple sclerosis pathology with magnetic resonance

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 4, 2006, Pages 295-306

  Ge, Yulin ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atrophy; Diffusion tensor imaging; Inflammation; MRI; MRS; Multiple sclerosis; Normal appearing white matter; Quantitative

Indexed keywords

CHOLINE; CREATINE PHOSPHATE; GADOLINIUM; N ACETYLASPARTIC ACID; STEROID;

BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN SIZE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION TENSOR IMAGING; HUMAN; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; MAGNETIC FIELD; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT OUTCOME; WHITE MATTER;

CONTRAST MEDIA; DISEASE PROGRESSION; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 34247119143     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e3180417d14     Document Type: Review

References (123)

1. Hickey WF. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol. 1999;98:37-44.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
3. Hemmer B, Kieseier B, Cepok S, et al. New immunopathologic insights into multiple sclerosis. Curr Neurol Neurosci Rep. 2003;3:246-255.
4. Grossman RI, McGowan JC. Perspectives on multiple sclerosis. AJNR Am J Neuroradiol. 1998;19:1251-1265.
5. Adams CW, Poston RN, Buk SJ, et al. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci. 1985;69:269-283.
6. Grossman RI, Braffman BH, Brorson JR, et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology. 1988;169:117-122.
7. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 1990;40:229-235.
8. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging. 1997;7:29-37.
9. Guttmann CR, Ahn SS, Hsu L, et al. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol. 1995;16:1481-1491.
10. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol. 1993;33:18-27.
11. Masdeu JC, Moreira J, Trasi S, et al. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging. 1996;6:104-107.
12. Barkhof F, Scheltens P, Frequin ST, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992;159:1041-1047.
13. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480-489.
14. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353:964-969.
15. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(Pt 4):927-939.
16. Tortorella C, Codella M, Rocca MA, et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol. 1999;246:689-692.
17. Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler. 2001;7:75-82.
18. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 1999;6:455-459.
19. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717.
20. Lai M, Hodgson T, Gawne-Cain M, et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:339-341.
21. Koziol JA, Wagner S, Sobel DF, et al. Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2001;22:284Y291.
22. Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci. 2000;176:42-44.
23. Ormerod IE, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987;110(Pt 6):1579-1616.
24. Wattjes MP, Lutterbey GG, Harzheim M, et al. Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. Eur Radiol. 2006;16:1494-1500.
25. Horowitz AL, Kaplan RD, Grewe G, et al. The ovoid lesion: a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol. 1989;10:303-305.
26. Adams CW, Abdulla YH, Torres EM, et al. Periventricular lesions in multiple sclerosis: their perivenous origin and relationship to granular ependymitis. Neuropathol Appl Neurobiol. 1987;13:141-152.
27. Ge Y, Law M, Herbert J, et al. Prominent perivenular spaces in multiple sclerosis as a sign of perivascular inflammation in primary demyelination. AJNR Am J Neuroradiol. 2005;26:2316-2319.
28. McFarland HF, Stone LA, Calabresi PA, et al. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198-205.
29. Miller DH. Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force. Mult Scler. 1996;1:335-338.
30. De Groot CJ, Bergers E, Kamphorst W, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain. 2001;124(Pt 8):1635-1645.
31. Engelbrecht V, Rassek M, Preiss S, et al. Age-dependent changes in magnetization transfer contrast of white matter in the pediatric brain. AJNR Am J Neuroradiol. 1998;19:1923-1929.
32. van Buchem MA, Steens SC, Vrooman HA, et al. Global estimation of myelination in the developing brain on the basis of magnetization transfer imaging: a preliminary study. AJNR Am J Neuroradiol. 2001;22:762-766.
33. Loevner LA, Grossman RI, McGowan JC, et al. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. AJNR Am J Neuroradiol. 1995;16:1473-1479.
34. Petrella JR, Grossman RI, McGowan JC, et al. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol. 1996;17:1041-1049.
35. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992;182:483-491.
36. Mehta RC, Pike GB, Enzmann DR. Measure of magnetization transfer in multiple sclerosis demyelinating plaques, white matter ischemic lesions, and edema. AJNR Am J Neuroradiol. 1996;17:1051-1055.
37. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56:407-415.
38. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998;19:675-683.
39. Loevner LA, Grossman RI, Cohen JA, et al. Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology. 1995;196:511-515.
40. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995;45(Pt 1):478-482.
41. Guo AC, Jewells VL, Provenzale JM. Analysis of normal-appearing white matter in multiple sclerosis: comparison of diffusion tensor MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol. 2001;22:1893-1900.
42. Ge Y, Grossman RI, Babb JS, et al. Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol. 2003;24:1935-1940.
43. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809-814.
44. Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000;215:824-830.
45. Catalaa I, Grossman RI, Kolson DL, et al. Multiple sclerosis: magnetization transfer histogram analysis of segmented normal-appearing white matter. Radiology. 2000;216:351-355.
46. Rocca MA, Cercignani M, Iannucci G, et al. Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology. 2000;55:882-884.
47. Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol. 2002;249:1382-1390.
48. Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B. 1994;103:247-254.
49. Rovira A, Pericot I, Alonso J, et al. Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. AJNR Am J Neuroradiol. 2002;23:989-994.
50. Fazzone HE, Lefton DR, Kupersmith MJ. Acute occipital demyelinating lesion appearing as an infarct on diffusion magnetic resonance imaging. Am J Ophthalmol. 2003;135:96-97.
51. Kuker W, Ruff J, Gaertner S, et al. Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology. 2004;46:421-426.
52. Bernarding J, Braun J, Koennecke HC. Diffusion- and perfusion-weighted MR imaging in a patient with acute demyelinating encephalomyelitis (ADEM). J Magn Reson Imaging. 2002;15:96-100.
53. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003;206:187-191.
54. Gass A, Niendorf T, Hirsch JG. Acute and chronic changes of the apparent diffusion coefficient in neurological disorders-biophysical mechanisms and possible underlying histopathology. J Neurol Sci. 2001;186(suppl 1):S15-S23.
55. Caramia F, Pantano P, Di Legge S, et al. A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magn Reson Imaging. 2002;20:383-388.
56. Griffin CM, Chard DT, Ciccarelli O, et al. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Mult Scler. 2001;7:290-297.
57. Ge Y, Law M, Johnson G, et al. Preferential occult injury of corpus callosum in multiple sclerosis measured by diffusion tensor imaging. J Magn Reson Imaging. 2004;20:1-7.
58. Ciccarelli O, Werring DJ, Barker GJ, et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging - evidence of Wallerian degeneration. J Neurol. 2003;250:287-292.
59. Evangelou N, Esiri MM, Smith S, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol. 2000;47:391-395.
60. Song SK, Sun SW, Ju WK, et al. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage. 2003;20:1714-1722.
61. Jones DK, Simmons A, Williams SC, et al. Non-invasive assessment of axonal fiber connectivity in the human brain via diffusion tensor MRI. Magn Reson Med. 1999;42:37-41.
62. Soohoo S, Ge Y, Law M, et al. Lesional fractional anisotropy, diffusivity and fiber tractography in patients with multiple sclerosis with DTI at 3 Tesla. Paper presented at: Proceedings of the 43rd Annual Meeting of the American Society of Neuroradiology; 2005; Toronto, Canada.
63. Ge Y, Tuvia K, Law M, et al. Corticospinal tract degeneration in brainstem in patients with multiple sclerosis: evaluation with diffusion tensor tractography. In: Proceedings of the 13th International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meeting, Miami Beach, Florida, 2005;2803.
64. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
65. Putnam TJ. Lesions of Fencephalomyelitis' and multiple sclerosis: venous thrombosis as the primary alteration. JAMA. 1937;108:1477-1480.
66. Graham EM, Stanford MR, Sanders MD, et al. A point prevalence study of 150 patients with idiopathic retinal vasculitis: 1. Diagnostic value of ophthalmological features. Br J Ophthalmol. 1989;73:714-721.
67. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51:260-265.
68. Wakefield AJ, More LJ, Difford J, et al. Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol. 1994;47:129-133.
69. Law M, Saindane AM, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology. 2004;231:645-652.
70. Ge Y, Law M, Johnson G, et al. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol. 2005;26:1539-1547.
71. Karonen JO, Vanninen RL, Liu Y, et al. Combined diffusion and perfusion MRI with correlation to single-photon emission CT in acute ischemic stroke. Ischemic penumbra predicts infarct growth. Stroke. 1999;30:1583-1590.
72. Hatazawa J, Shimosegawa E, Toyoshima H, et al. Cerebral blood volume in acute brain infarction: a combined study with dynamic susceptibility contrast MRI and 99mTc-HMPAO-SPECT. Stroke. 1999;30:800-806.
73. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol. 2004;56:308.
74. Wuerfel J, Bellmann-Strobl J, Brunecker P, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain. 2004;127(Pt 1):111-119.
75. Broom KA, Anthony DC, Blamire AM, et al. MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain. J Cereb Blood Flow Metab. 2005;25:204-216.
76. Sims DE. Recent advances in pericyte biology - implications for health and disease. Can J Cardiol. 1991;7:431-443.
77. De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995;38:901-909.
78. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999;20:1619-1627.
79. Davies SE, Newcombe J, Williams SR, et al. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem. 1995;64:742-748.
80. Inglese M, Li BS, Rusinek H, et al. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med. 2003;50:190-195.
81. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117(Pt 1):49-58.
82. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 1990;40:1764-1769.
83. Narayana PA, Wolinsky JS, Jackson EF, et al. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging. 1992;2:263-270.
84. Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol. 2000;21:1220-1227.
85. De Stefano N, Bartolozzi ML, Guidi L, et al. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci. 2005;233:203-208.
86. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127(pt 6):1361-1369.
87. Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2002;8:207-210.
88. Kapeller P, Ropele S, Enzinger C, et al. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative (1)H-magnetic resonance spectroscopy. J Neurol. 2005;252:1229-1234.
89. Casanova B, Martinez-Bisbal MC, Valero C, et al. Evidence of Wallerian degeneration in normal appearing white matter in the early stages of relapsing-remitting multiple sclerosis: a HMRS study. J Neurol. 2003;250:22-28.
90. Ge Y, Gonen O, Inglese M, et al. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology. 2004;62:624-627.
91. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:646-651.
92. Rao SM, Glatt S, Hammeke TA, et al. Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. Arch Neurol. 1985;42:678-682.
93. Dietemann JL, Beigelman C, Rumbach L, et al. Multiple sclerosis and corpus callosum atrophy: relationship of MRI findings to clinical data. Neuroradiology. 1988;30:478-480.
94. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125(Pt 8):1676-1695.
95. Xu J, Kobayashi S, Yamaguchi S, et al. Gender effects on age-related changes in brain structure. AJNR Am J Neuroradiol. 2000;21:112-118.
96. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;214:665-670.
97. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology. 2000;54:807-812.
98. Kalkers NF, Ameziane N, Bot JC, et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol. 2002;59:1572-1576.
99. Ge Y, Grossman RI, Babb JS, et al. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol. 2002;23:1327-1333.
100. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology. 2001;220:606-610.
101. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology. 2002;59:688-694.
102. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology. 2001;57:1253-1258.
103. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54:813-817.
104. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000;123(Pt 11):2256-2263.
105. Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000;6:365-372.
106. Keiper MD, Grossman RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T. AJNR Am J Neuroradiol. 1998;19:1489-1493.
107. Beard JL, Connor JR, Jones BC. Iron in the brain. Nutr Rev. 1993;51:157-170.
108. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res. 1996;145:532-541.
109. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 1997;760:298-303.
110. Craelius W, Migdal MW, Luessenhop CP, et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med. 1982;106:397-399.
111. Drayer B, Burger P, Hurwitz B, et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? AJR Am J Roentgenol. 1987;149:357-363.
112. Jensen JH, Chandra R, Ramani A, et al. Magnetic field correlation imaging. Magn Reson Med. 2006;55:1350-1361.
113. LeVine SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses. 1992;39:271-274.
114. Russo C, Smoker WR, Kubal W. Cortical and subcortical T2 shortening in multiple sclerosis. AJNR Am J Neuroradiol. 1997;18:124-126.
115. Grimaud J, Millar J, Thorpe JW, et al. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995;59:306-308.
116. Bakshi R, Dmochowski J, Shaikh ZA, et al. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci. 2001;185:19-26.
117. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol. 2005;62:1371-1376.
118. Ge Y, Jensen JH, Lu H, et al. Iron accumulation in the deep gray matter of patients with multiple sclerosis measured by magnetic field correlation. AJNR Am J Neuroradiol. 2007. In press.
119. Wylezinska M, Cifelli A, Jezzard P, et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology. 2003;60:1949-1954.
120. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004;52:612-618.
121. Reichenbach JR, Barth M, Haacke EM, et al. High-resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr. 2000;24:949-957.
122. Rauscher A, Sedlacik J, Barth M, et al. Nonnvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med. 2005;54:87-95.
123. Brooks DJ, Leenders KL, Head G, et al. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984;47:1182-1191.